Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 16, Issue 1, 1997, Pages 22-30

  Ioannidis, John P A ^a,e   Bassett, Roland ^b   Hughes, Michael D ^b,f   Volberding, Paul A ^c   Sacks, Henry S ^d   Lau, Joseph ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antiretroviral therapy; Bias; Clinical trials; Loss to follow up; Treatment effect; Withdrawals; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0030833490     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199709010-00004     Document Type: Article

References (32)

1. Volberding PA, Lagakos SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995;333:401-7.
2. Sande MA, Carpenter CC, Cobbs CG, et al. Antiretroviral therapy in adult HIV-infected patients: recommendations from a state-of-the art conference. JAMA 1993;270:2583-9.
3. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
4. Ho DD. Time to hit HIV: early, and hard. N Engl J Med 1995; 333:450-1,
5. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each participant. I: analysis and examples. Br J Cancer 1977;35:1-39.
6. Cox DR. Regression models and life tables. J R Stat Soc 1972;34: 187-202.
7. SAS Inc. SAS for personal computers. Cary, NC: SAS Inc., 1993.
8. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science 1995;270:1372-5.
9. Prevots DR, Allen DM, Lehman JS, Green TA, Petersen LR, Gwinn M. Trends in human immunodeficiency virus seroprevalence among injection drug users entering drug treatment centers. United States, 1988-93. Am J Epidemiol 1996;143:733-42.
10. Caldwell RA, Cox LE, Morse EV, et al. HIV/AIDS communitybased clinical trials achieve low lost-to-follow up rates [abstract 6.1596]. In: Abstracts of the XI International Conference on AIDS, Vancouver. Canada, July 7-12, 1996.
11. Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:455-9.
12. Eldred L, Wu A, Chaisson RE, Moore RD. Adherence to antiretroviral therapy [abstract 251]. In: Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997.
13. Schapiro JM, Winters MA, Vierra M, el al. Causes of long-term efficacy and/or drug failure in protease inhibitor monotherapy [abstract Mo.B.414]. In: Abstracts of the XI International Conference on AIDS, Vancouver, Canada, July 7-12, 1996.
14. Sylvester RJ, Pinedo HM, De Pauw M, et al. Quality of institutional participation in multicenter clinical trials. N Engl J Med 1981;305:852-5.
15. Hawkins BS, Prior MJ, Fisher MR, Blackhurst DW. Relationship between rate of patient enrollment and quality of clinical center performance in two multicenter trials in ophthalmology. Controlled Clin Trials 1990;11:374-94.
16. Rosendorf LL, Dafni U, Amato DA, et al. Performance evaluation in multicenter clinical trials: development of a model by the AIDS Clinical Trials Group. Controlled Clin Trials 1993;14:523-37.
17. Stone VE, Seage GR 3rd, Hertz T, Epstein AM. The relationship between hospital experience and mortality for patients with AIDS. JAMA 1992;268:2655-61.
18. Meinert CL, Tonascia S. Clinical trials: design, conduct, and analysis. New York: Oxford University Press, 1986.
19. Pocock SJ. Clinical trials: a practical approach. Chichester: John Wiley and Sons, 1983.
20. Costagliola D, Krause M. Zidovudine in HIV infection [letter]. Ann Intern Med 1996;124:372.
21. Ioannidis JP, Lau J, Sacks HS. Zidovudine in HIV infection [letter]. Ann Intern Med 1996;124:372-3.
22. 3 [abstract 198]. In: Abstracts of the Third Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28-February 1, 1996.
23. Raboud JM, Montaner JSG, Thorne A, Singer J, Schechter MT, Canadian HIV Trials Network A002 Study Group. Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12: 46-55.
24. Hogan CH, Hodges JS, Mugglin A, et al. The perils of visit-driven endpoints in antiretroviral trials [abstract Tu.B.552]. In: Abstracts of the XI International Conference on AIDS, Vancouver, Canada, July 7-12, 1996.
25. Ioannidis JP, Cappelleri JC, Lau J, et al. Early or deferred zidovudine in HIV-infected patients without an AIDS-defining illness: a meta-analysis. Ann Intern Med 1995;122:855-66.
26. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free individuals. Lancet 1994;343:871-81.
27. Montaner JS, Hogg R, Srour LF, et al. Should we embrace new drugs with open arms? Experience from a community-based, openarm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:422-6.
28. Ioannidis JPA, Cappelleri JC, Schmid CH, Lau J. Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates: an example from patient populations in trials of human immunodeficiency virus infection. Am J Epidemiol 1996;144:1074-85.
29. Ioannidis JPA, Sacks HS, Cappelleri JC, Lau J. Clinical efficacy of antiretroviral changes in treatment-experienced HIV-infected patients: a metaanalysis [doc. no. 204], Online J Curr Clin Trials, May 15, 1997.
30. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
31. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
32. National Center for Health Statistics. National Death Index: user's manual. HHS publ no. (PHS) 81-1148, Hyattsville, Maryland, 1981.